par Body, Jean-Jacques
;Bergmann, Pierre
;Boonen, Steven;Boutsen, Yves;Devogelaer, J.-P.;Goemaere, Stefan;Kaufman, Jean-Marc;Rozenberg, Serge
;Reginster, Jean-Yves
Référence Osteoporosis international, 21, 10, page (1657-1680)
Publication Publié, 2010-10



Référence Osteoporosis international, 21, 10, page (1657-1680)
Publication Publié, 2010-10
Article révisé par les pairs
Résumé : | Several drugs are available for the management of postmenopausal osteoporosis. This may, in daily practice, confuse the clinician. This manuscript offers an evidence-based update of previous treatment guidelines, with a critical assessment of the currently available efficacy data on all new chemical entities which were granted a marketing authorization. Osteoporosis is widely recognized as a major public health concern. The availability of new therapeutic agents makes clinical decision-making in osteoporosis more complex. Nation-specific guidelines are needed to take into consideration the specificities of each and every health care environment. The present manuscript is the result of a National Consensus, based on a systematic review and a critical appraisal of the currently available literature. It offers an evidence-based update of previous treatment guidelines, with the aim of providing clinicians with an unbiased assessment of osteoporosis treatment effect. |